Global Multiplex Assay Market: Latest Developmental Insights
                     Global Multiplex Assay Market: Latest 
Developmental Insights
Recent years have seen a paradigm shift in the healthcare and biotechnology 
industries due to the introduction of cutting-edge technologies. Among these 
advancements is the emergence of multiplex assays, which have transformed how 
researchers approach diagnostic and research applications. By consolidating 
multiple assays into a single platform, researchers can streamline the analysis of 
complex biological samples, resulting in time and cost savings. According to Inkwood
Research, the global multiplex assays market is expected to register 
a CAGR of 8.12% during 2024-2032 and reach a revenue of $7793.26 
million by 2032. 
Multiplex assays have been widely adopted across diverse fields, such as clinical 
diagnostics, drug discovery, genomics, and proteomics. This blog details the latest 
developments happening in the global multiplex assay market.
Request a FREE sample of the Multiplex Assay Market
 Latest Developments in the Global Multiplex Assay Market
 Parhelia’s Omni-Stainer™: Enhanced and Automated Multiplex Assay
Understanding cellular function within a given microenvironment has become 
standard practice rather than an exception in life sciences research. The intricate 
relationships between cells and tissues dictate health outcomes, while molecular 
interactions within and among cells provide crucial context for understanding their 
collective effects.
 
Utilizing omics techniques to explore these relationships within native tissue 
environments offers spatial insight into cell heterogeneity and dynamics. This 
approach sheds light on disease progression, treatment responses, and genotype-
phenotype correlations at both cellular and tissue levels. However, the accuracy of 
these maps depends on the quality of the underlying data.
Implementing automated sample preparation methods enhances data consistency, 
reproducibility, and throughput, particularly crucial for multiplex assays prone to 
manual variability and time constraints. Parhelia Biosciences envisioned an 
affordable solution to standardize multiplex assays, ensuring consistent and 
reproducible data across laboratories of all sizes.
The Parhelias’ Omni-Stainer™, a fully automated system, comprises a robotic 
chassis, thermal module, flow cells, software, and the company’s S12 staining 
module accommodating up to 12 slide-mounted samples. Staining employs capillary 
gap exchange, ensuring uniform coverage, minimal reagent waste, and simplified 
stain removal. Additionally, a dedicated thermal module sustains precise 
temperature control (0-99.9°C) for incubation.
Affordability was a key consideration in developing the Parhelia Omni-Stainer, as 
similar automated systems typically cost between $300,000 to $500,000, making 
them inaccessible to many laboratories. This drove the team to pursue an open-
source approach during the development of CODEX (now PhenoCycler) at Stanford 
University’s Nolan Lab.
Explains Nikolay Samusik, Ph.D., co-founder and CEO of Parhelia, “Our experience
demonstrated that accuracy in these assays doesn’t require paying too much for the 
fastest, shiniest system, which won’t automatically translate into solid data,” Samusik
explains. “This drove our vision to own the spatial biology workflow by providing 
open-source solutions that enable labs of all sizes to streamline and standardize 
assay performance to ensure consistency and reproducibility.” (Source)
Get CUSTOMIZED market insights delivered right to your inbox!
 Enabling Comprehensive Quantification: Navigate BioPharma Services 
Inc’s Cutting-Edge Multiplex Digital PCR Assay
In the 2023 AAPS National Biotechnology Conference, Navigate BioPharma 
Services Inc, a subsidiary of Novartis known for its groundbreaking biomarker 
solutions in drug development, introduced its latest innovation: multiplex digital PCR 
assays. These assays provide a comprehensive means of quantifying multiple 
chimeric antigen receptor (CAR) T cells, a form of cancer immunotherapy that 
modifies T cells genetically to target and eliminate specific cancers. Leveraging 
the Qiagen QIAcuity digital PCR System, these assays offer a robust and user-
friendly digital PCR experience facilitated by its innovative nanoplate system.
The innovative multiplex digital PCR assay facilitates simultaneous assessment of 
the quantity, activity, and persistence of CAR-T cells in clinical blood and bone 
marrow samples, eliminating the necessity for a standard curve. It boasts a 
sensitivity capable of detecting CAR-T cells as minute as 0.01% within normal T cell 
populations, delivering results in under two hours. 
Further, this assay accommodates the measurement of up to five distinct CAR-T cell 
markers within a single reaction, utilizing specific probes tailored to different CAR 
targets, thus enabling the quantification of multiple CAR-domains or combinations of 
commonly utilized therapeutic targets in CAR-T therapies. Such capabilities 
empower clinicians to monitor response rates and safety profiles throughout clinical 
trials, facilitating the advancement of novel therapeutic approaches.
Says Dr. Nathan Riccitelli, Associate Director of Innovative Technologies 
at Navigate BioPharma Services Inc, “CAR-T therapy is a promising and 
innovative approach to treat cancer, but it requires accurate and reliable 
quantification of CAR-T cells for successful drug development. Our new proprietary 
multiplex digital PCR assay provides a comprehensive and robust solution for 
measuring CAR-T cells in clinical samples with high sensitivity, specificity and 
reproducibility.” (Source)
Stay up-to-date with what’s trending in the Global Multiplex Assay Market
Future Potential of Multiplex Assay Market
The development of multiplex tests enables the simultaneous measurement of 
multiple analytes in a single biological sample, minimizing assay time, cost, and 
sample volume. For instance, a multiplex test for respiratory viruses could deliver 
sensitive and accurate results right in the doctor’s office, facilitating immediate 
treatment initiation. 
Furthermore, multiplex testing aids laboratories in conserving vital testing supplies 
such as pipettes, swabs, and reagents, all of which are in high demand. Additionally, 
it reduces reliance on single-use tests and enables labs to offer more comprehensive
results in a shorter timeframe.
Moreover, studies have demonstrated that rapid multiplex testing reduces the length 
of stay (LOS) for ICU patients from 9.2 to 6.2 days (P < 0.0001). In a period marked 
by boarding and hospital overcrowding, a shorter LOS during ‘tripledemics’ 
enhances patient flow, thereby enhancing hospital productivity. Accordingly, the 
current and imminent global healthcare landscape offers lucrative growth 
opportunities for the global multiplex assay market.
Can’t find what you’re looking for? Talk to an expert NOW!
1. What are multiplex assays?
A: Multiplex assays are diagnostic tests that allow the simultaneous detection 
and measurement of multiple analytes in a single sample, streamlining the 
testing process and providing comprehensive results.
2. What are the benefits of using multiplex assays?
A: Using multiplex assays offers several advantages, including reduced assay
time, cost-effectiveness, conservation of testing supplies, and the ability to 
provide comprehensive diagnostic information with minimal sample volume.
3. How are multiplex assays impacting the healthcare industry?
A: Multiplex assays are revolutionizing diagnostics in the healthcare industry 
by improving efficiency, accuracy, and turnaround time for testing. They play a
crucial role in various applications, including disease diagnosis, drug 
discovery, biomarker analysis, and personalized medicine, driving 
advancements in patient care and treatment outcomes.